Anixa Biosciences Enters Into Development And Manufacturing Agreement With Cytovance Biologics To Produce cGMP Clinical Materials For Planned Phase 2 Clinical Trial Of Breast Cancer Vaccine

Anixa Biosciences has entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its planned Phase 2 clinical trial of a breast cancer vaccine. This follows the successful completion of a Phase 1 study, which met all primary endpoints, demonstrated safety and tolerability, and generated immune responses in 74% of participants. The vaccine targets α-lactalbumin, a protein associated with breast tissue and certain breast cancers, aiming to provide therapeutic and preventive benefits.